245 related articles for article (PubMed ID: 37450122)
21. Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care.
Hedtke M; Pessoa Rejas R; Froelich MF; Ast V; Duda A; Mirbach L; Costina V; Martens UM; Hofheinz RD; Neumaier M; Haselmann V
Mol Oncol; 2022 May; 16(10):2042-2056. PubMed ID: 34873826
[TBL] [Abstract][Full Text] [Related]
22. Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019.
Christou N; Meyer J; Popeskou S; David V; Toso C; Buchs N; Liot E; Robert J; Ris F; Mathonnet M
Biomed Res Int; 2019; 2019():5953036. PubMed ID: 31930130
[TBL] [Abstract][Full Text] [Related]
23. Circulating biomarkers for early detection and clinical management of colorectal cancer.
Marcuello M; Vymetalkova V; Neves RPL; Duran-Sanchon S; Vedeld HM; Tham E; van Dalum G; Flügen G; Garcia-Barberan V; Fijneman RJ; Castells A; Vodicka P; Lind GE; Stoecklein NH; Heitzer E; Gironella M
Mol Aspects Med; 2019 Oct; 69():107-122. PubMed ID: 31189073
[TBL] [Abstract][Full Text] [Related]
24. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y; Yoshino T
Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients.
Yang YC; Wang D; Jin L; Yao HW; Zhang JH; Wang J; Zhao XM; Shen CY; Chen W; Wang XL; Shi R; Chen SY; Zhang ZT
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29914973
[TBL] [Abstract][Full Text] [Related]
26. Perspectives of the Application of Liquid Biopsy in Colorectal Cancer.
Ding Y; Li W; Wang K; Xu C; Hao M; Ding L
Biomed Res Int; 2020; 2020():6843180. PubMed ID: 32258135
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
[TBL] [Abstract][Full Text] [Related]
28. The detection of specific hypermethylated WIF1 and NPY genes in circulating DNA by crystal digital PCR™ is a powerful new tool for colorectal cancer diagnosis and screening.
Overs A; Flammang M; Hervouet E; Bermont L; Pretet JL; Christophe B; Selmani Z
BMC Cancer; 2021 Oct; 21(1):1092. PubMed ID: 34627187
[TBL] [Abstract][Full Text] [Related]
29. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor DNA as a biomarker in metastatic colorectal carcinoma case report.
Menclová K; Pudil J; Benešová L; Hálková T; Ptáčková R; Semyakina A; Minárik M; Levý M; Šimša J; Pazdírek F; Hoch J; Bláha M; Ryska M
Rozhl Chir; 2020; 99(4):179-182. PubMed ID: 32545981
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.
Gao Z; Huang D; Chen H; Yang Y; An K; Ding C; Yuan Z; Zhai Z; Niu P; Gao Q; Cai J; Zeng Q; Wang Y; Hong Y; Rong W; Huang W; Lei F; Wang X; Chen S; Zhao X; Bai Y; Gu J
J Transl Med; 2023 Jan; 21(1):63. PubMed ID: 36717891
[TBL] [Abstract][Full Text] [Related]
32. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
[TBL] [Abstract][Full Text] [Related]
33. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
34. Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy.
Verbanac D; Čeri A; Hlapčić I; Shakibaei M; Brockmueller A; Krušlin B; Ljubičić N; Baršić N; Detel D; Batičić L; Rumora L; Somborac-Bačura A; Štefanović M; Ćelap I; Demirović A; Petlevski R; Petrik J; Grdić Rajković M; Hulina-Tomašković A; Rako I; Saso L; Barišić K
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919272
[TBL] [Abstract][Full Text] [Related]
35. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.
Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066
[TBL] [Abstract][Full Text] [Related]
36. Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer.
Osumi H; Shinozaki E; Ooki A; Shimozaki K; Kamiimabeppu D; Nakayama I; Wakatsuki T; Ogura M; Takahari D; Chin K; Yamaguchi K
Cancer Med; 2021 Dec; 10(24):8820-8828. PubMed ID: 34821068
[TBL] [Abstract][Full Text] [Related]
37. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.
Normanno N; Cervantes A; Ciardiello F; De Luca A; Pinto C
Cancer Treat Rev; 2018 Nov; 70():1-8. PubMed ID: 30053724
[TBL] [Abstract][Full Text] [Related]
38. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.
Raza A; Khan AQ; Inchakalody VP; Mestiri S; Yoosuf ZSKM; Bedhiafi T; El-Ella DMA; Taib N; Hydrose S; Akbar S; Fernandes Q; Al-Zaidan L; Krishnankutty R; Merhi M; Uddin S; Dermime S
J Exp Clin Cancer Res; 2022 Mar; 41(1):99. PubMed ID: 35292091
[TBL] [Abstract][Full Text] [Related]
39. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
Bent A; Raghavan S; Dasari A; Kopetz S
Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.
Fakih M; Sandhu J; Wang C; Kim J; Chen YJ; Lai L; Melstrom K; Kaiser A
JAMA Netw Open; 2022 Mar; 5(3):e221093. PubMed ID: 35258578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]